Obrador, GregorioGregorioObradorPereira, Brian J.G.Brian J.G.Pereira2023-07-122023-07-122000https://scripta.up.edu.mx/handle/20.500.12552/362510.1177/089686080002002s27The prevalence of end-stage renal disease (ESRD) in the United States has more than doubled in the last decade and is expected to continue to increase (1). Total Medicare payments for ESRD by patient– year at risk have increased by 2.5% – 5.3% each year between 1991 and 1997, and the total annual cost was estimated to be in excess of $15 billion dollars in 1997 (2,3). Despite the significant resources committed to the ESRD program, survival among ESRD patients remains poor. Adjusted one-year, two-year, and five-year survival probabilities among dialysis patients are currently 80.7%, 65.4%, and 29.3% (2). Older age, male sex, Caucasian race, diabetes, and left ventricular hypertrophy have been shown to be associated with higher mortality among ESRD patients (4-7). In addition, the timing of initiation of dialysis has been incriminated as a possible factor that could affect ESRD outcomes. Copyright © 2000 International Society for Peritoneal DialysisenResource Types::text::journal::journal article